Harbor Light Capital Partners focuses on investments in the $1-$5 million range. Unlike institutional investment funds, we are not limited
Business Model: B2B
Revenue: $5.9M
Employees: 2-10
Address: 38 Central Sq
City: Keene
State: NH
Zip: 03431
Country: US
Harbor Light Capital Partners focuses on investments in the $1-$5 million range. Unlike institutional investment funds, we are not limited to traditional holding periods of 3 to 5 years. Therefore, we make decisions based on what is best for the growth and success of the business. Our investment flexibility, combined with our values, family legacy and management expertise, make us an attractive option for family-owned and emerging growth businesses seeking a long-term, value-adding partner. Early Stage Criteria: Technology or healthcare emphasis Innovative / disruptive technology Strong intellectual property position Large and attractive market opportunity Growth Stage Criteria: Product and / or geographic growth potential Strong historical / projected revenue growth Profitable, or will be within 12 months Preference for recurring revenue streams Companies with passionate, loyal customers Lower middle market, $1M to $25M in revenues Exceptional management teams with proven entrepreneurial leadership and vision Harbor Light team can add significant value to the business Value Generation Model Engage actively at the Board and operational level, and leverage Advisory Board expertise in finance, operations, marketing and technology Bring relationships and expertise for rapid growth; facilitate expansion through business networks Promote a long-term, relationship-based culture; develop and encourage business models built on “customer intimacy†Use financial leverage to improve risk/rewards profile; apply debt in prudent, strategic circumstances
Contact Phone:
+16033559954
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
7/2015 | Courtagen Life Sciences | Private Equity Round | 0 |
4/2011 | Carmell Therapeutics | Series A | 0 |
6/2014 | Carmell Therapeutics | Series A | 681.5k |
6/2011 | Draker | Venture Round | 3M |
6/2015 | Senet | Series A | 18M |
11/2013 | Terascala | Venture Round | - |
8/2008 | Draker | Series A | 1M |
8/2012 | Draker | Venture Round | 0 |
7/2017 | Carmell Therapeutics | Series B | 4M |
6/2012 | Vets First Choice | Venture Round | 0 |
2/2009 | FetchDog | Series A | 4M |
6/2010 | Micronotes | Seed Round | 1.7M |
10/2011 | Courtagen Life Sciences | Series B | 0 |
7/2013 | EnerTrac | Series A | - |
7/2009 | Eggrock Partners | Venture Round | 2.5M |
1/2014 | Alcyone Lifesciences | Series B | 4M |
7/2017 | Carmell Therapeutics | Series B | 0 |
7/2015 | Courtagen Life Sciences | Private Equity Round | 0 |
6/2015 | Senet | Series A | 0 |
6/2014 | Carmell Therapeutics | Series A | 0 |
1/2014 | Alcyone Lifesciences | Series B | 0 |
11/2013 | Terascala | Venture Round | - |
7/2013 | EnerTrac | Series A | - |
8/2012 | Draker | Venture Round | 0 |
6/2012 | Vets First Choice | Venture Round | 0 |
10/2011 | Courtagen Life Sciences | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|